High-throughput Sequencing Reveals Altered Expression of Hepatic MicroRNAs in Nonalcoholic Fatty Liver Disease-related Fibrosis
Overview
Authors
Affiliations
Recent evidence suggests that microRNAs (miRNAs), small, noncoding RNA molecules that regulate gene expression, may play a role in the regulation of metabolic disorders, including nonalcoholic fatty liver disease (NAFLD). To identify miRNAs that mediate NAFLD-related fibrosis, we used high-throughput sequencing to assess miRNAs obtained from liver biopsies of 15 individuals without NAFLD fibrosis (F0) and 15 individuals with severe NAFLD fibrosis or cirrhosis (F3-F4), matched for age, sex, body mass index, type 2 diabetes status, hemoglobin A1c, and use of diabetes medications. We used DESeq2 and Kruskal-Wallis test to identify miRNAs that were differentially expressed between NAFLD patients with or without fibrosis, adjusting for multiple testing using Bonferroni correction. We identified a total of 75 miRNAs showing statistically significant evidence (adjusted P value <0.05) for differential expression between the 2 groups, including 30 upregulated and 45 downregulated miRNAs. Quantitative reverse-transcription polymerase chain reaction analysis of selected miRNAs identified by sequencing validated 9 of 11 of the top differentially expressed miRNAs. We performed functional enrichment analysis of dysregulated miRNAs and identified several potential gene targets related to NAFLD-related fibrosis including hepatic fibrosis, hepatic stellate cell activation, transforming growth factor beta signaling, and apoptosis signaling. We identified forkhead box O3 and F-box WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182, and found that levels of forkhead box O3, but not FBXW7, were significantly decreased in fibrotic samples. These findings support a role for hepatic miRNAs in the pathogenesis of NAFLD-related fibrosis and yield possible new insight into the molecular mechanisms underlying the initiation and progression of liver fibrosis and cirrhosis.
Zhao Y, Li Y, Su M, Cai X Cent Eur J Immunol. 2025; 49(4):383-392.
PMID: 39944255 PMC: 11811718. DOI: 10.5114/ceji.2024.145730.
Krause C, Britsemmer J, Bernecker M, Molenaar A, Taege N, Lopez-Alcantara N Elife. 2024; 12.
PMID: 39037913 PMC: 11262792. DOI: 10.7554/eLife.92075.
Integrating Genetic and Transcriptomic Data to Identify Genes Underlying Obesity Risk Loci.
Xu H, Gupta S, Dinsmore I, Kollu A, Cawley A, Anwar M medRxiv. 2024; .
PMID: 38903089 PMC: 11188121. DOI: 10.1101/2024.06.11.24308730.
Khalifa O, Ouararhni K, Errafii K, Alajez N, Arredouani A Int J Mol Sci. 2023; 24(14).
PMID: 37511368 PMC: 10380891. DOI: 10.3390/ijms241411606.
Compagnoni C, Capelli R, Zelli V, Corrente A, Vecchiotti D, Flati I Int J Mol Sci. 2023; 24(11).
PMID: 37298191 PMC: 10252350. DOI: 10.3390/ijms24119239.